Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_2
2
40%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed240%
terminated240%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Optimized Erythropoietin (EPO) Treatment

NCT02075970
terminatedphase_3

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

NCT01695759
terminatedphase_4

Prevalence and Treatment of Anemia in Rehabilitation Patients

NCT00511901
completedphase_2

Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia

NCT00524901
unknownnot_applicable

Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model

NCT00691613

Clinical Trials (5)

Showing 5 of 5 trials
NCT02075970Phase 2

Optimized Erythropoietin (EPO) Treatment

Completed
NCT01695759Phase 3

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Terminated
NCT00511901Phase 4

Prevalence and Treatment of Anemia in Rehabilitation Patients

Terminated
NCT00524901Phase 2

Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia

Completed
NCT00691613Not Applicable

Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5